APA aipamena

Khan, K. H., Wong, M., Rihawi, K., Bodla, S., Morganstein, D., Banerji, U., & Molife, L. R. (2016). Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. Oncologist.

Chicago Style aipamena

Khan, Khurum H., Mabel Wong, Karim Rihawi, Shankar Bodla, Daniel Morganstein, Udai Banerji, and Lulama R. Molife. "Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management." Oncologist 2016.

MLA aipamena

Khan, Khurum H., et al. "Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management." Oncologist 2016.